Werewolf Therapeutics, Inc. (HOWL): Price and Financial Metrics

Werewolf Therapeutics, Inc. (HOWL): $7.91

0.56 (+7.62%)

POWR Rating

Component Grades








Add HOWL to Watchlist
Sign Up

Industry: Biotech




#65 of 357

in industry

HOWL Price/Volume Stats

Current price $7.91 52-week high $8.19
Prev. close $7.35 52-week low $1.57
Day low $7.38 Volume 242,000
Day high $8.14 Avg. volume 290,597
50-day MA $5.02 Dividend yield N/A
200-day MA $3.27 Market Cap 321.63M

HOWL Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where HOWL ranks best; there it ranks ahead of 96.76% of US stocks.
  • The strongest trend for HOWL is in Quality, which has been heading up over the past 26 weeks.
  • HOWL's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).

HOWL Stock Summary

  • WEREWOLF THERAPEUTICS INC's stock had its IPO on April 30, 2021, making it an older stock than just 7.55% of US equities in our set.
  • With a year-over-year growth in debt of 244.18%, WEREWOLF THERAPEUTICS INC's debt growth rate surpasses 96.33% of about US stocks.
  • Revenue growth over the past 12 months for WEREWOLF THERAPEUTICS INC comes in at 182.13%, a number that bests 97.22% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to WEREWOLF THERAPEUTICS INC are ONCT, QURE, TRDA, TCRX, and IKNA.
  • Visit HOWL's SEC page to see the company's official filings. To visit the company's web site, go to werewolftx.com.

HOWL Valuation Summary

  • In comparison to the median Healthcare stock, HOWL's price/sales ratio is 145.45% higher, now standing at 5.4.
  • HOWL's price/sales ratio has moved NA NA over the prior 32 months.

Below are key valuation metrics over time for HOWL.

Stock Date P/S P/B P/E EV/EBIT
HOWL 2023-12-29 5.4 1.2 -3.7 -1.7
HOWL 2023-12-28 5.8 1.3 -4.0 -1.9
HOWL 2023-12-27 5.5 1.3 -3.8 -1.7
HOWL 2023-12-26 5.0 1.1 -3.4 -1.3
HOWL 2023-12-22 4.5 1.0 -3.1 -1.0
HOWL 2023-12-21 4.2 1.0 -2.9 -0.8

HOWL Price Target

For more insight on analysts targets of HOWL, see our HOWL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.40 Average Broker Recommendation 1.2 (Strong Buy)

Werewolf Therapeutics, Inc. (HOWL) Company Bio

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

HOWL Latest News Stream

Event/Time News Detail
Loading, please wait...

HOWL Latest Social Stream

Loading social stream, please wait...

View Full HOWL Social Stream

Latest HOWL News From Around the Web

Below are the latest news stories about WEREWOLF THERAPEUTICS INC that investors may wish to consider to help them evaluate HOWL as an investment opportunity.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shareholders would be excited to see that the share price has had a great...

Yahoo | December 14, 2023

Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$14m last week but private equity firms profited the most

Key Insights Werewolf Therapeutics' significant private equity firms ownership suggests that the key decisions are...

Yahoo | December 7, 2023

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside c

Yahoo | November 22, 2023

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity – – Safety data indicate WTX-124 is generally well tolerated through cohort 4 (12 mg), with a wide therapeutic index supportive of continued dose escalation – – Additional interim WTX-124 monotherapy data and recommended dose for expansion expected in the first half of 2024 – – Announcing the addition of

Yahoo | November 14, 2023

CVNA Stock Alert: What Analysts Are Saying After Carvana’s Q3 Earnings

Carvana stock is on the move as analysts weigh in on CVNA shares following the release of the company's latest earnings report.

William White on InvestorPlace | November 3, 2023

Read More 'HOWL' Stories Here

HOWL Price Returns

1-mo 81.84%
3-mo 207.78%
6-mo 188.69%
1-year 166.33%
3-year N/A
5-year N/A
YTD 104.92%
2023 88.29%
2022 -82.79%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!